Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Sareum Holdings plc operates as a specialized pharmaceutical company, primarily focused on discovering and advancing innovative therapeutic compounds for treating both cancer and autoimmune conditions. The firm develops small-molecule drugs, utilizing its proprietary Sareum Kinase Inhibitor Library as its core drug discovery platform. Its development portfolio currently features programs targeting Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. Sareum has also forged strategic partnerships with the Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. Founded in 2003, the company is headquartered in Cambridge, United Kingdom.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers.
Target Price
The average target price of SAR.L is 41.6 and suggests 51.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc